Bioventus (NYSE:BVS) Releases FY 2025 Earnings Guidance

Key Points

• Bioventus has updated its FY 2025 earnings guidance, projecting EPS of 0.640-0.680, lower than the consensus estimate of 0.707, and revenue guidance of $560.0 million-$570.0 million compared to a consensus of $565.2 million.
• The company’s stock traded down 5.8% to $6.87 following the guidance update, with a market cap of $563.92 million and a price-to-earnings ratio of -11.25.
• Institutional investors hold 62.94% of Bioventus stock, with a recent stake increase by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. of 7.2% in the first quarter.

Bioventus (NYSE:BVS - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.707. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $565.2 million.

Bioventus Trading Down 5.8%

BVS traded down $0.43 on Thursday, reaching $6.87. 416,367 shares of the company's stock were exchanged, compared to its average volume of 392,604. The company's 50 day moving average is $6.65 and its 200-day moving average is $8.06. Bioventus has a twelve month low of $5.81 and a twelve month high of $14.38. The company has a market cap of $563.92 million, a price-to-earnings ratio of -11.25 and a beta of 0.83. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BVS shares. Craig Hallum set a $15.00 price target on Bioventus and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Cantor Fitzgerald assumed coverage on shares of Bioventus in a research report on Monday, July 7th. They issued an "overweight" rating and a $12.00 target price for the company.

Institutional Investors Weigh In On Bioventus

A hedge fund recently raised its stake in Bioventus stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 7.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,048 shares of the company's stock after acquiring an additional 1,538 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Bioventus were worth $211,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 62.94% of the company's stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.